New chemo cocktail shows promise in shrinking pancreatic tumors before surgery
NCT ID NCT03483038
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase II trial is testing a combination of liposomal irinotecan (Onivyde) and FOLFOX chemotherapy given before surgery to people with pancreatic cancer that can be removed. The study includes 45 adults with early-stage disease. The goal is to see if this approach is safe and helps patients complete surgery with fewer complications.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
liposomal irinotecan (Onivyde) plus FOLFOX chemotherapy (oxaliplatin, leucovorin, 5-fluorouracil)
What this could lead to
If successful, this combination could become a standard pre-surgery treatment to improve surgical outcomes and survival for pancreatic cancer patients.
What could go wrong
This is a small, early-phase study with no control group. The treatment may cause significant side effects, and results may not apply to all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Indiana University Melvin and Bren Simon Cancer Center
Indianapolis, Indiana, 46202, United States
-
Orlando Health UF Health Cancer Center
Orlando, Florida, 32806, United States
-
Tallahassee Memorial Health Care
Tallahassee, Florida, 32308, United States
-
University of Florida
Gainesville, Florida, 32608, United States